184 related articles for article (PubMed ID: 22099257)
1. Design, synthesis, and evaluation of novel small molecule inhibitors of the influenza virus protein NS1.
Jablonski JJ; Basu D; Engel DA; Geysen HM
Bioorg Med Chem; 2012 Jan; 20(1):487-97. PubMed ID: 22099257
[TBL] [Abstract][Full Text] [Related]
2. Exploring naphthyl-carbohydrazides as inhibitors of influenza A viruses.
Barman S; You L; Chen R; Codrea V; Kago G; Edupuganti R; Robertus J; Krug RM; Anslyn EV
Eur J Med Chem; 2014 Jan; 71():81-90. PubMed ID: 24287556
[TBL] [Abstract][Full Text] [Related]
3. Novel inhibitor of influenza non-structural protein 1 blocks multi-cycle replication in an RNase L-dependent manner.
Walkiewicz MP; Basu D; Jablonski JJ; Geysen HM; Engel DA
J Gen Virol; 2011 Jan; 92(Pt 1):60-70. PubMed ID: 20881091
[TBL] [Abstract][Full Text] [Related]
4. Structure and Activities of the NS1 Influenza Protein and Progress in the Development of Small-Molecule Drugs.
Kim HJ; Jeong MS; Jang SB
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921888
[TBL] [Abstract][Full Text] [Related]
5. Identification, design and synthesis of novel pyrazolopyridine influenza virus nonstructural protein 1 antagonists.
Patnaik S; Basu D; Southall N; Dehdashti S; Wan KK; Zheng W; Ferrer M; Taylor M; Engel DA; Marugan JJ
Bioorg Med Chem Lett; 2019 May; 29(9):1113-1119. PubMed ID: 30852083
[TBL] [Abstract][Full Text] [Related]
6. A Comprehensive Insight into the Chemical Space and ADME Features of Small Molecule NS5A Inhibitors.
Ivanenkov YA; Veselov MS; Shakhbazyan AG; Aladinskiy VA; Aladinskaya AV; Yartseva SM; Majouga AG; Vantskul AS; Leonov SV; Ivachtchenko AV; Koteliansky VE
Curr Top Med Chem; 2016; 16(12):1372-82. PubMed ID: 26585933
[TBL] [Abstract][Full Text] [Related]
7. In Silico Approaches to the Design of NS5A Inhibitors.
Ivanenkov YA; Veselov MS; Aladinskiy VA; Shakhbazyan AG; Yartseva SM; Majouga AG; Aladinskaya AV; Vantskul AS; Leonov SV; Ivachtchenko AV; Koteliansky VE
Curr Top Med Chem; 2016; 16(12):1383-91. PubMed ID: 26585932
[TBL] [Abstract][Full Text] [Related]
8. The influenza virus NS1 protein as a therapeutic target.
Engel DA
Antiviral Res; 2013 Sep; 99(3):409-16. PubMed ID: 23796981
[TBL] [Abstract][Full Text] [Related]
9. Quantitative proteomic analysis of the influenza A virus nonstructural proteins NS1 and NS2 during natural cell infection identifies PACT as an NS1 target protein and antiviral host factor.
Tawaratsumida K; Phan V; Hrincius ER; High AA; Webby R; Redecke V; Häcker H
J Virol; 2014 Aug; 88(16):9038-48. PubMed ID: 24899174
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
[TBL] [Abstract][Full Text] [Related]
11. Identification of a Pyridoxine-Derived Small-Molecule Inhibitor Targeting Dengue Virus RNA-Dependent RNA Polymerase.
Xu HT; Colby-Germinario SP; Hassounah S; Quashie PK; Han Y; Oliveira M; Stranix BR; Wainberg MA
Antimicrob Agents Chemother; 2016 Jan; 60(1):600-8. PubMed ID: 26574011
[TBL] [Abstract][Full Text] [Related]
12. High-Throughput Screening Identifies Inhibitors for Parvovirus B19 Infection of Human Erythroid Progenitors.
Ning K; Roy A; Cheng F; Xu P; Kleiboeker S; Escalante CR; Wang J; Qiu J
J Virol; 2022 Jan; 96(2):e0132621. PubMed ID: 34669461
[TBL] [Abstract][Full Text] [Related]
13. De novo design approaches targeting an envelope protein pocket to identify small molecules against dengue virus.
Leal ES; Adler NS; Fernández GA; Gebhard LG; Battini L; Aucar MG; Videla M; Monge ME; Hernández de Los Ríos A; Acosta Dávila JA; Morell ML; Cordo SM; García CC; Gamarnik AV; Cavasotto CN; Bollini M
Eur J Med Chem; 2019 Nov; 182():111628. PubMed ID: 31472473
[TBL] [Abstract][Full Text] [Related]
14. Chemical inhibition of RNA viruses reveals REDD1 as a host defense factor.
Mata MA; Satterly N; Versteeg GA; Frantz D; Wei S; Williams N; Schmolke M; Peña-Llopis S; Brugarolas J; Forst CV; White MA; García-Sastre A; Roth MG; Fontoura BM
Nat Chem Biol; 2011 Sep; 7(10):712-9. PubMed ID: 21909097
[TBL] [Abstract][Full Text] [Related]
15. Development of an HTS assay for the search of anti-influenza agents targeting the interaction of viral RNA with the NS1 protein.
Maroto M; Fernandez Y; Ortin J; Pelaez F; Cabello MA
J Biomol Screen; 2008 Aug; 13(7):581-90. PubMed ID: 18594021
[TBL] [Abstract][Full Text] [Related]
16. Author's overview: identifying SARS-CoV-2 antiviral compounds.
Diffley JFX
Biochem J; 2021 Jul; 478(13):2533-2535. PubMed ID: 34198320
[TBL] [Abstract][Full Text] [Related]
17. Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease.
Ren J; Ojeda I; Patel M; Johnson ME; Lee H
Bioorg Med Chem Lett; 2019 Aug; 29(16):2349-2353. PubMed ID: 31201062
[TBL] [Abstract][Full Text] [Related]
18. Influenza virus non-structural protein NS1: interferon antagonism and beyond.
Marc D
J Gen Virol; 2014 Dec; 95(Pt 12):2594-2611. PubMed ID: 25182164
[TBL] [Abstract][Full Text] [Related]
19. Structural analyses reveal the mechanism of inhibition of influenza virus NS1 by two antiviral compounds.
Kleinpeter AB; Jureka AS; Falahat SM; Green TJ; Petit CM
J Biol Chem; 2018 Sep; 293(38):14659-14668. PubMed ID: 30076219
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and evaluation against Chikungunya virus of novel small-molecule antiviral agents.
Tardugno R; Giancotti G; De Burghgraeve T; Delang L; Neyts J; Leyssen P; Brancale A; Bassetto M
Bioorg Med Chem; 2018 Feb; 26(4):869-874. PubMed ID: 29336951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
